Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 643-647

  Lu, Xueying ^a   Wei, Haibo ^a   Zhang, Xiaojin ^a   Zheng, Wenxin ^a   Chang, Cheng ^b   Jinyu, Gu ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Colon cancer; Oxaliplatin; Rapamycin

Indexed keywords

ACRIDINE ORANGE; LIPOCORTIN 5; OXALIPLATIN; RAPAMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRUCTURE; CHROMATIN CONDENSATION; COLON CANCER; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IC 50; PROTEIN EXPRESSION;

EID: 79958039858     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.299     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. McWhinney SR, Goldberg RM and McLeod HL: Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8: 10-16, 2009.
3. Gerber DE and Choy H: Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev 29: 171-180, 2010.
4. Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J and Gil-Bazo I: Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 28: 5867-5876, 2007.
5. Wadlow RC and Ryan DP: The role of targeted agents in preoperative chemoradiation for rectal cancer. Cancer 116: 3537-3548, 2010.
6. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210: 767-776, 2010.
7. Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E and Colucci G: The dark side of the moon: the PI3K/PTEN/AKT pathway in colo-rectal carcinoma. Oncology 77 Suppl 1: 69-74, 2009.
8. Merimsky O, Gorzalczany Y and Sagi-Eisenberg R: Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol 31: 225-232, 2007.
9. Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP and Guenot D: Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 15: 1297-1307, 2009.
10. Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F and Gianni L: Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 28: 4554-4561, 2010.
11. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L and Smith MA: Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9: 101-112, 2010
12. Eisenberg-Lerner A, Bialik S, Simon HU and Kimchi A: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966-975, 2009.
13. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH and Anderson KC: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104: 4188-4193, 2004.
14. Gu J, Yamamoto H, Lu X, Ngan CY, Tsujino T, Konishi K, Takemasa I, Ikeda M, Nagata H, Hashimoto S, Matsuzaki T, Sekimoto M, Takagi A and Monden M: Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 74: 19-27, 2006.
15. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 439-444, 2001.
16. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML and Kiernan MC: Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27: 1243-1249, 2009.
17. Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T and Taniguchi S: Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol 37: 1001-1010, 2010.
18. Shigematsu H, Yoshida K, Sanada Y, Osada S, Takahashi T, Wada Y, Konishi K, Okada M and Fukushima M: Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int J Cancer 126: 2716-2725, 2010.
19. Fung AS, Wu L and Tannock IF: Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 15: 5389-5395, 2009.
20. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC and Ghobrial IM: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12: 6826-6835, 2006.
21. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004.
22. Shafer A, Zhou C, Gehrig PA, Boggess JF and Bae-Jump VL: Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126: 1144-1154, 2010.
23. Bae-Jump VL, Zhou C, Boggess JF and Gehrig PA: Synergistic effect of rapamycin\ and cisplatin in endometrial cancer cells. Cancer 115: 3887-3896, 2009.
24. Kondo Y and Kondo S: Autophagy and cancer therapy. Autophagy 2: 85-90, 2006.